Nucleus Network

Executive Summary

Nucleus Network is a leading global contract research organization (CRO) specializing in early-phase (Phase I) clinical trials for novel biological entities, biosimilars, and vaccines. Founded in 1993 and headquartered in Brisbane, Australia, the company operates purpose-built, hospital-integrated facilities in Australia, the United States, and the United Kingdom. Its unique co-location model enables accelerated patient recruitment and access to specialized medical infrastructure, supporting high-quality safety and efficacy data generation. With an in-house participant database and expertise in pharmacokinetic, hepatic, and renal studies, Nucleus Network offers integrated services that streamline drug development for biotech and pharmaceutical sponsors. The company employs 500–1,000 staff and has established a strong reputation for reliability and scientific rigor in the competitive CRO market.

Upcoming Catalysts (preview)

• Q2 2026Completion of New U.S. Clinical Facility80% success
• Q3 2026Strategic Partnership with Major Biopharma60% success
• Q4 2026Launch of Cell & Gene Therapy Service Line70% success